Wegovy vs Mounjaro: How Ingredients, Effects, Administration, and Side Effects Differ

As the weight-loss injections Wegovy and Mounjaro are increasingly discussed, many people wonder how the two drugs differ. In short, they belong to similar drug classes, but their ingredients, mechanisms of action, and approved indications are different. Above all, these drugs are not “weight-loss supplements”; they are prescription medicines that require a doctor’s prescription. This article is a neutral reference summary of those differences.

Key differences at a glance

• Wegovy: Its active ingredient is semaglutide (Novo Nordisk). It acts on GLP-1 only, is given as a once-weekly subcutaneous injection, and is approved in Korea for obesity treatment, with launch in 2024.
• Mounjaro: Its active ingredient is tirzepatide (Eli Lilly). It acts simultaneously on two hormones, GIP and GLP-1, as a dual-action drug, and is given as a once-weekly subcutaneous injection. In Korea, Mounjaro is indicated for type 2 diabetes; in the United States, the same ingredient is approved for obesity under a different name, Zepbound.
• Both drugs work by suppressing appetite and slowing gastric emptying, thereby reducing food intake.
• Ozempic and Saxenda, also from Novo Nordisk, are GLP-1-class drugs such as semaglutide and liraglutide.

Mechanism of action: Why does appetite decrease?

Both drugs mimic GLP-1, a hormone released by the body when we eat. This hormone acts on the brain’s appetite center to increase satiety and slows the movement of food out of the stomach, helping people feel full despite eating less. The biggest structural difference from Wegovy is that Mounjaro’s tirzepatide is a dual-action drug that also acts on another gut hormone called GIP.

How different are the effects?

In clinical trials, both drugs showed meaningful weight reduction, and some comparisons report that dual-action tirzepatide produced greater average weight loss. However, these are only clinical averages, and individual differences are very large. Even with the same drug, the effect can be larger or smaller depending on the person, and it is heavily influenced by whether lifestyle habits such as diet and exercise are maintained. No drug “helps” guarantee a specific percentage of weight loss, and treating these drugs as “miracle medicines” is risky.

Common side effects and safety precautions

• The most common side effects are gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, usually appearing early when the dose is gradually increased.
• Rare cases of pancreatitis and gallstones have been reported, and persistent severe abdominal pain requires immediate medical care.
• Both drugs carry a boxed warning because thyroid C-cell tumors were observed in rodent studies, so they are contraindicated for people with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
• People who are pregnant or breastfeeding, or who have severe gastrointestinal disease, should consult a doctor before use whenever possible.

Oral GLP-1 obesity drugs are still in the development and approval stage

Many people who find injections burdensome are waiting for an oral obesity drug. Orforglipron, being developed by Eli Lilly, is known to be an oral GLP-1-class drug that has gone through phase 3 trials and is in the approval process. However, this remains a development and approval-stage outlook; the specific domestic launch date, price, brand name, and insurance coverage status have not been confirmed and may change. Information suggesting that a specific product name such as “Pounjaro” has already been launched or confirmed is not factual, so please verify related details directly through the latest official news.

Essential principles to remember

• These drugs are prescribed at a doctor’s discretion when indications such as BMI are met. They are not medicines to use on your own simply because you want to lose weight.
• Using unofficial channels such as overseas direct purchases, online purchases, or transfers from acquaintances carries high risks of counterfeit drugs, dosing errors, and side effects.
• If the medication is stopped, appetite can return and weight may increase again, known as weight regain, so lifestyle management needs to continue alongside treatment.
• If prescribed outside insurance coverage, the cost can be high, and price and coverage status vary depending on timing and indication.

Notice and disclaimer